Brief: Denali Therapeutics Inc Says Additional Interim Data From DNL310 Phase 1/2 Study Will Be Presented at SSIEM Symposium In August
20/06/2023 12:22
June 20 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS INC -
* DENALI THERAPEUTICS INC - ANNOUNCES ROBUST REDUCTION IN
NEUROFILAMENT LIGHT (NFL) WITH DNL310 (ETV:IDS) TREATMENT IN MPS
II (HUNTER SYNDROME)
* DENALI - INTERIM RESULTS SHOW AVERAGE REDUCTION OF 64% (P
<0.001) FROM BASELINE IN SERUM NFL AFTER 2 YEARS OF DOSING WITH
DNL310 IN PHASE 1/2 STUDY
* DENALI THERAPEUTICS INC - ADDITIONAL INTERIM DATA FROM
DNL310
PHASE 1/2 STUDY WILL BE PRESENTED AT SSIEM SYMPOSIUM IN AUGUST
Source text for Eikon: ID:nGNX54GMNr
Further company coverage: DNLI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers